Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-α-2 in combination with 5-FU

Urological Research

Volumn 24, Issue 5, 1996, Pages 297-303

  Gohring B ^a   Riemann, D ^a   Rebmaan, U ^b   Heynemann, H ^a   Schabel, J ^a   Langner, J ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Anhaltische Diakonissenanstalt D ^*  (Germany)

Author keywords

CD4; Interferon therapeutic use; Interleukin 2 therapeutic use; Renal cell carcinoma; T lymphocytes

Indexed keywords

ALPHA2B INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; FLUOROURACIL; HLA DR ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2;

ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; INTERFERON ALFA-2B; INTERLEUKIN-2; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; PROGNOSIS; T-LYMPHOCYTE SUBSETS;

EID: 0029852590     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00304780     Document Type: Article

References (30)

1. Abbate I, Correale M, Musci MD, Guida M, Dragone CD, De Santis M, De Lena M (1993) Modification of soluble immunological parameters during treatment with interleukin-2. Int J Biol Markers 8:227
2. Atzpodien J, Kirchner H, Hanninen EL, Deckert M, Fenner M, Poliwoda H (1993) Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 29A (Suppl 5):6
3. Atzpodien J, Kirchner H, Korfer A, Hadam M, Schomburg A, Menzel T, Deckert M, Franzke A, Volkenandt M, Dallmann I, et al (1993) Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-α-2. Tumour Biol 14:354
4. Baiocchi C, Landonio G, Balzarini G, Cacioppo C, Calgaro M, Ferrari M, Gottardi O, Majno M, Scanzi F, Ghisalandi E, Brando B (1994) Possible correlation between some biological effects and the clinical course in patients treated with continuous infusion of interleukin-2 plus α-2 interferon for metastatic renal cell carcinoma. Tumori 80:358
5. Bergmann L (1989) Malignant melanoma. Prognosis and actual treatment strategies with chemotherapy and biological response modifiers. Eur J Clin Oncol 23 (Suppl 3):31
6. Buzaid AC, Todd MB (1989) Therapeutic options in renal cell carcinoma. Semin Oncol 16:12
7. De Riese W, Allhoff E, Kirchner, H, Stief LG, Atzpodien J, Maschek H, Jonas V (1991) Complete spontaneous regression in metastatic renal cell carcinoma: an update and review. World J Urol 9:184
8. Dünsing S, Hadam M, Korfer A, Schomburg A, Menzel T, Grosse AU, Kirchner H, Poliwoda H, Atzpodien J (1992) Pretreatment natural killer antigen density correlates to clinical response in tumour patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-α. Mol Biother 4:170
9. Figlin RA, Abi-Aad AS, Belldegrun A, de Kernion JB (1991) The role of IFN and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma. Semin Oncol 18:102
10. Figlin RA, Belldegrun A, Moldawer N, Zeffren J, de Kernion JB (1992) Concomitant administration of recombinant human interleukin-2 and recombinant interferon-α-2: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 10:414
11. + tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res 50:2363
12. Hannet P, Erkeller-Yuksel F, Lydyard P, Deneys V, DeBruyere M (1992) Developmental and maturational changes in human blood lymphocyte subpopulations. Immunol Today 13:215
13. Hermanek P, Schrott KM (1990) Evaluation of the new tumor, nodes and metastasis classification of renal cell carcinoma. J Urol 144:238
14. Hillman GG, Pun RK, Kukuruga MA (1994) Growth and major histocompatibility expression regulation by IL-4, interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α) on human renal carcinoma. Clin Exp Immunol 96:476-483
15. Kobayashi Y, Yuzawa M, Sugaya Y, Kikuchi T, Monta T, Tokue A (1994) Changes of lymphocyte subpopulation in advanced renal cell carcinoma patients with marked response to alpha-interferon therapy. Nippon Hinyokika Gakkai Zasshi 85:1380
16. Lopez-Hanninen E, Poliwoda H, Atzpodien J (1995) Interferon-α/5 fluorouracil: a novel outpatient chemo-/immunotherapy for progressive metastatic renal cell carcinoma. Cancer Biother 10:21
17. Martens A, Janssen RA, Sleijfer DT, Heijn AA, Mulder NH, The TH, de Leij L (1993) Early sCD8 plasma levels during subcutaneous rIL-2 therapy in patients with renal cell carcinoma correlate with response. Br J Cancer 67:1118
18. Meffert M, Schomburg A, Hanninen EL, Menzel T, Vocke S, Dallmann I, Grosse J, Duensing S, Buer J, Kirchner H (1995) In vivo tumor necrosis factor-α as indicator of biologic and clinical response to low-dose SC recombinant interleukin 2. Anticancer Res 15:127
19. Obiri NL Hillmann GG, Haas GP (1993) Expression of high affinity interleukin-4 receptors on human renal carcinoma cells and investigation of tumor cell growth in vitro by interleukin-4. J Clin Invest 91:88-93
20. Raymond E, Boaziz C, Komarover H, Breau JL, Moliard M, Morere JF, Israel L (1993) Cancer of the kidney: changes in blood lymphocyte subsets induced by treatment with interferon-α-2b and interleukin-2r. Bull Cancer Paris 80:299
21. Rodgers S, Rees RC, Hancock BW (1994) Changes in the phenotypic characteristics of eosinophils from patients receiving recombinant human interleukin-2 (rhIL-2) therapy. Br J Haematol 86:746
22. Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmüller G, Segurado OG (1993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes; I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 151:4209
23. Schneekloth C, Korfer A, Hadam M, Lopez Hanninen E, Menzel T, Schomburg A, Dallmann I, Kirchner H, Poliwoda H, Atzpodien J (1993) Low dose interleukin-2 in combination with interferon-α effectively modulates biological response in vivo. Acta Haematol 89:13
24. + T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells. Cell Immunol 150:114
25. Sella A, Kilbourn RG, Gray I, Finn L, Zukiwski AA, Ellerhorst J, Amato RJ, Logothetis CJ (1994) Phase I study of imerleukin-2 combined with interferon-α and 5-fluorouracil in patients with metastatic renal cell cancer. Cancer Biother 9:103
26. Stadler WM, Rybak ME, Vogelzang NJ (1995) A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma. Cancer 76:1629
27. Studnica M, Wirnsberger R, Neumann M, Pokieser L, Angerler J (1994) Peripheral blood lymphocytes subsets and survival in small-cell lung cancer. Chest 105:1673
28. Thiounn N, Mathiot C, Flam T, Tartour E, Peyret C, Joyeux I, Abecassis JP, Zerbib M, Fridman WH, Debre B (1994) CD4 TIL (tumor infiltrating lymphocytes) induce complete response in patients treated with IL-2 (interleukin-2). Preliminary study. J Urol Paris 100:185
29. Weiss GR, Margolin KA, Sznol M, Atkins MB, Oleksowicz L, Isaacs R, Sosman JA, Doroshow JH, Rehu EG, Dutcher JB, Fisher R (1995) A phase II study of the continuous intervenons infusion of interleukin-6 for metastatic renal cell carcinoma. J Immunother 18:92
30. Wirth MP (1993) Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 20: 283